Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Progyny Inc’s stock clocked out at $23.78, up 1.62% from its previous closing price of $23.4. In other words, the price has increased by $1.62 from its previous closing price. On the day, 0.88 million shares were traded. PGNY stock price reached its highest trading level at $24.23 during the session, while it also had its lowest trading level at $23.6.
Ratios:
To gain a deeper understanding of PGNY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.75. For the most recent quarter (mrq), Quick Ratio is recorded 2.70 and its Current Ratio is at 2.70. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On December 02, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $17.
Truist Downgraded its Buy to Hold on November 13, 2024, whereas the target price for the stock was revised from $26 to $19.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 11 ’25 when GORDON KEVIN K sold 2,500 shares for $22.04 per share. The transaction valued at 55,088 led to the insider holds 12,501 shares of the business.
GORDON KEVIN K bought 2,500 shares of PGNY for $55,088 on Aug 11 ’25. On Jun 11 ’25, another insider, Scott Cheryl, who serves as the Director of the company, sold 2,675 shares for $22.07 each. As a result, the insider received 59,037 and left with 14,112 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PGNY now has a Market Capitalization of 2044661504 and an Enterprise Value of 1768198656. As of this moment, Progyny’s Price-to-Earnings (P/E) ratio for their current fiscal year is 40.37, and their Forward P/E ratio for the next fiscal year is 26.86. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.65 while its Price-to-Book (P/B) ratio in mrq is 3.97. Its current Enterprise Value per Revenue stands at 1.424 whereas that against EBITDA is 21.886.
Stock Price History:
The Beta on a monthly basis for PGNY is 1.33, which has changed by 0.1291548 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, PGNY has reached a high of $26.76, while it has fallen to a 52-week low of $13.39. The 50-Day Moving Average of the stock is 5.89%, while the 200-Day Moving Average is calculated to be 15.96%.
Shares Statistics:
It appears that PGNY traded 1.10M shares on average per day over the past three months and 1348290 shares per day over the past ten days. A total of 85.93M shares are outstanding, with a floating share count of 78.71M. Insiders hold about 8.46% of the company’s shares, while institutions hold 90.39% stake in the company. Shares short for PGNY as of 1753920000 were 7756843 with a Short Ratio of 7.08, compared to 1751241600 on 7300580. Therefore, it implies a Short% of Shares Outstanding of 7756843 and a Short% of Float of 12.479999999999999.
Earnings Estimates
As of right now, 6.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.38, with high estimates of $0.4 and low estimates of $0.36.
Analysts are recommending an EPS of between $1.78 and $1.72 for the fiscal current year, implying an average EPS of $1.74. EPS for the following year is $1.82, with 7.0 analysts recommending between $2.05 and $1.63.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $298.33M. It ranges from a high estimate of $304.2M to a low estimate of $290M. As of the current estimate, Progyny Inc’s year-ago sales were $286.62MFor the next quarter, 10 analysts are estimating revenue of $302.76M. There is a high estimate of $312.66M for the next quarter, whereas the lowest estimate is $283.34M.
A total of 9 analysts have provided revenue estimates for PGNY’s current fiscal year. The highest revenue estimate was $1.27B, while the lowest revenue estimate was $1.24B, resulting in an average revenue estimate of $1.26B. In the same quarter a year ago, actual revenue was $1.17BBased on 9 analysts’ estimates, the company’s revenue will be $1.38B in the next fiscal year. The high estimate is $1.48B and the low estimate is $1.31B.
